ICE (chemotherapy)
# ICE (chemotherapy)

ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma.

In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.

[R]-ICE regimen consists of:

* Rituximab - an anti-CD20 monoclonal antibody, which is able to kill both normal and malignant CD20-bearing B cells;
* Ifosfamide - an alkylating antineoplastic agent of the oxazafosforine group;
* Carboplatin - a platinum-based antineoplastic drug, also an alkylating antineoplastic agent;
* Etoposide - a topoisomerase inhibitor.

## Dosing regimen

| Drug | Dose | Mode | Days |
| - | - | - | - |
| Rituximab | 375 $mg/m^2$ | IV infusion | Day 1 |
| Ifosfamide | 5000 $mg/m^2$ | IV continuous infusion over 24 hours | Day 2 |
| Mesna for haemorrhagic cystitis prophylaxis with ifosfamide | 5000 $mg/m^2$ | IV continuous infusion over 24 hours | Day 2 |
| Carboplatin | Optimized to get AUC = 5 (max. 800 mg) | IV infusion | Day 2 |
| Etoposide | 100 $mg/m^2$ | IV infusion over 1 hour | Days 1-3 |
| Filgrastim to shorten the period of neutropenia | 5 µg/kg | S.C. | Days 5-12 |

Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT).

